Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 607-617

  Wu, Jennifer ^a,b   Yu, Evan ^c,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Division of Cancer Prevention and Control Hollings National Cancer Institute Designated Cancer Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d USA   (United States)

Author keywords

IGF IR; Mechanisms; Metastasis; Prostate cancer; Therapy

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; SOMATOMEDIN C RECEPTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; MALE; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84905097153     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9482-0     Document Type: Review

References (105)

1. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63, 11-30.
2. Gennigens, C., Menetrier-Caux, C., & Droz, J. P. (2006). Insulin-like growth factor (IGF) family and prostate cancer. Critical Reviews in Oncology/Hematology, 58, 124-145.
3. Kojima, S., Inahara, M., Suzuki, H., Ichikawa, T., & Furuya, Y. (2009). Implications of insulin-like growth factor-I for prostate cancer therapies. International Journal of Urology, 16, 161-167.
4. Baserga, R., Porcu, P., Rubini, M., & Sell, C. (1993). Cell cycle control by the IGF-1 receptor and its ligands. Advances in Experimental Medicine and Biology, 343, 105-112. (Pubitemid 24059281)
5. Adams, T. E., Epa, V. C., Garrett, T. P., & Ward, C. W. (2000). Structure and function of the type 1 insulin-like growth factor receptor. Cellular and Molecular Life Sciences : CMLS, 57, 1050-1093.
6. Baserga, R., Peruzzi, F., & Reiss, K. (2003). The IGF-1 receptor in cancer biology. International Journal of Cancer, 107, 873-877. (Pubitemid 37429826)
7. Cruickshank, J., Grossman, D. I., Peng, R. K., Famula, T. R., & Oberbauer, A. M. (2005). Spatial distribution of growth hormone receptor, insulin-like growth factor-I receptor and apoptotic chondrocytes during growth plate development. The Journal of Endocrinology, 184, 543-553. (Pubitemid 40426017)
8. Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P. (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Reviews, 28, 20-47. (Pubitemid 46220849)
9. DeAngelis, T., Wu, K., Pestell, R., & Baserga, R. (2011). The type 1 insulin-like growth factor receptor and resistance to DACH1. Cell Cycle, 10, 1956-1959.
10. Goel, H. L., Sayeed, A., Breen, M., Zarif, M. J., Garlick, D. S., Leav, I., Davis, R. J., Fitzgerald, T. J., Morrione, A., Hsieh, C. C., Liu, Q., Dicker, A. P., Altieri, D. C., & Languino, L. R. (2013). Beta1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase1. Journal of Cellular Physiology, 228(7), 1601-1609.
11. Casa, A. J., Dearth, R. K., Litzenburger, B. C., Lee, A. V., & Cui, X. (2008). The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Frontiers in Bioscience, 13, 3273-3287. (Pubitemid 351594682)
12. Helle, S. I. (2004). The insulin-like growth factor system in advanced breast cancer. Best Practice & Research. Clinical Endocrinology & Metabolism, 18, 67-79.
13. Pollak, M., Beamer, W., & Zhang, J. C. (1998). Insulin-like growth factors and prostate cancer. Cancer Metastasis Reviews, 17, 383-390.
14. Gross, J. M., & Yee, D. (2003). The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. Cancer Metastasis Reviews, 22, 327-336.
15. Polychronakos, C., Janthly, U., Lehoux, J. G., & Koutsilieris, M. (1991). Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. Prostate, 19, 313-321.
16. Werner, H., & Maor, S. (2006). The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends in Endocrinology and Metabolism: TEM, 17, 236-242.
17. Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A., & Friend, K. E. (2000). The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Reviews, 21, 215-244. (Pubitemid 32275588)
18. DiGiovanni, J., Kiguchi, K., Frijhoff, A., Wilker, E., Bol, D. K., Beltran, L., Moats, S., Ramirez, A., Jorcano, J., & Conti, C. (2000). Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 97, 3455-3460. (Pubitemid 30183324)
19. Chen, C. F., Li, S., Chen, Y., Chen, P. L., Sharp, Z. D., & Lee, W. H. (1996). The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. The Journal of Biological Chemistry, 271, 32863-32868. (Pubitemid 27008717)
20. Hellawell, G. O., Turner, G. D., Davies, D. R., Poulsom, R., Brewster, S. F., & Macaulay, V. M. (2002). Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Research, 62, 2942-2950. (Pubitemid 34525783)
21. Krueckl, S. L., Sikes, R. A., Edlund, N. M., Bell, R. H., Hurtado-Coll, A., Fazli, L., Gleave, M. E., & Cox, M. E. (2004). Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Research, 64, 8620-8629. (Pubitemid 39552075)
22. Nickerson, T., Chang, F., Lorimer, D., Smeekens, S. P., Sawyers, C. L., & Pollak, M. (2001). In vivo progression of LAPC-9 and LNCaP prostate cancermodels to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGFI receptor (IGF-IR). Cancer Research, 61, 6276-6280. (Pubitemid 32762567)
23. Plymate, S. R., Bae, V. L., Maddison, L., Quinn, L. S., & Ware, J. L. (1997). Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology, 138, 1728-1735. (Pubitemid 27137128)
24. Kaplan, P. J., Mohan, S., Cohen, P., Foster, B. A., & Greenberg, N. M. (1999). The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Research, 59, 2203-2209. (Pubitemid 29217686)
25. Stattin, P., Rinaldi, S., Biessy, C., Stenman, U. H., Hallmans, G., & Kaaks, R. (2004). High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. Journal of Clinical Oncology, 22, 3104-3112. (Pubitemid 41103723)
26. Mantzoros, C. S., Tzonou, A., Signorello, L. B., Stampfer, M., Trichopoulos, D., & Adami, H. O. (1997). Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. British Journal of Cancer, 76, 1115-1118. (Pubitemid 27448004)
27. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 279, 563-566. (Pubitemid 28067285)
28. Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergstrom, R., Signorello, L. B., Lagiou, P., Adami, H. O., & Trichopoulos, D. (1998). Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. Journal of the National Cancer Institute, 90, 911-915. (Pubitemid 28304159)
29. Harman, S. M., Metter, E. J., Blackman, M. R., Landis, P. K., & Carter, H. B. (2000). Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. The Journal of Clinical Endocrinology and Metabolism, 85, 4258-4265. (Pubitemid 32055383)
30. Renehan, A. G., Zwahlen, M., Minder, C., O'Dwyer, S. T., Shalet, S. M., & Egger, M. (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 363, 1346-1353. (Pubitemid 38529873)
31. Chokkalingam, A. P., Pollak, M., Fillmore, C. M., Gao, Y. T., Stanczyk, F. Z., Deng, J., Sesterhenn, I. A., Mostofi, F. K., Fears, T. R., Madigan, M. P., Ziegler, R. G., Fraumeni, J. F., Jr., & Hsing, A. W. (2001). Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiology, Biomarkers & Prevention, 10, 421-427. (Pubitemid 32701626)
32. Platz, E. A., Pollak, M. N., Leitzmann, M. F., Stampfer, M. J., Willett, W. C., & Giovannucci, E. (2005). Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes & Control : CCC, 16, 255-262.
33. Woodson, K., Tangrea, J. A., Pollak, M., Copeland, T. D., Taylor, P. R., Virtamo, J., & Albanes, D. (2003). Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Research, 63, 3991-3994. (Pubitemid 36917917)
34. Chen, C., Lewis, S. K., Voigt, L., Fitzpatrick, A., Plymate, S. R., & Weiss, N. S. (2005). Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer, 103, 76-84. (Pubitemid 39665459)
35. Allen, N. E., Key, T. J., Appleby, P. N., Travis, R. C., Roddam, A. W., Rinaldi, S., Egevad, L., Rohrmann, S., Linseisen, J., Pischon, T., Boeing, H., Johnsen, N. F., Tjonneland, A., Gronbaek, H., Overvad, K., Kiemeney, L., Bueno-de-Mesquita, H. B., Bingham, S., Khaw, K. T., Tumino, R., Berrino, F., Mattiello, A., Sacerdote, C., Palli, D., Quiros, J. R., Ardanaz, E., Navarro, C., Larranaga, N., Gonzalez, C., Sanchez, M. J., Trichopoulou, A., Travezea, C., Trichopoulos, D., Jenab, M., Ferrari, P., Riboli, E., & Kaaks, R. (2007). Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology, Biomarkers & Prevention, 16, 1121-1127. (Pubitemid 46984947)
36. Sutherland, B. W., Knoblaugh, S. E., Kaplan-Lefko, P. J., Wang, F., Holzenberger, M., & Greenberg, N. M. (2008). Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Research, 68, 3495-3504.
37. LeRoith, D., & Roberts, C. T., Jr. (2003). The insulin-like growth factor system and cancer. Cancer Letters, 195, 127-137.
38. Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. (2009). Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine Reviews, 30, 586-623.
39. Dallas, N. A., Xia, L., Fan, F., Gray, M. J., Gaur, P., Van Buren, G., 2nd, Samuel, S., Kim, M. P., Lim, S. J., & Ellis, L. M. (2009). Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Research, 69, 1951-1957.
40. He, Y., Zhang, J., Zheng, J., Du, W., Xiao, H., Liu, W., Li, X., Chen, X., Yang, L., & Huang, S. (2010). The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells. Oncology Research, 19, 35-43.
41. Morrione, A., Romano, G., Navarro, M., Reiss, K., Valentinis, B., Dews, M., Eves, E., Rosner, M. R., & Baserga, R. (2000). Insulin-like growth factor I receptor signaling in differentiation of neuronal H19-7 cells. Cancer Research, 60, 2263-2272. (Pubitemid 30225193)
42. Valentinis, B., Romano, G., Peruzzi, F., Morrione, A., Prisco, M., Soddu, S., Cristofanelli, B., Sacchi, A., & Baserga, R. (1999). Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. The Journal of Biological Chemistry, 274, 12423-12430.
43. Gronborg, M., Wulff, B. S., Rasmussen, J. S., Kjeldsen, T., & Gammeltoft, S. (1993). Structure-function relationship of the insulin-like growth factor-I receptor tyrosine kinase. The Journal of Biological Chemistry, 268, 23435-23440. (Pubitemid 23328068)
44. Li, S., Ferber, A., Miura, M., & Baserga, R. (1994). Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. The Journal of Biological Chemistry, 269, 32558-32564.
45. Rubinstein, M., Idelman, G., Plymate, S. R., Narla, G., Friedman, S. L., & Werner, H. (2004). Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology, 145, 3769-3777. (Pubitemid 39037564)
46. Schayek, H., Haugk, K., Sun, S., True, L. D., Plymate, S. R., & Werner, H. (2009). Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clinical Cancer Research, 15, 1558-1565.
47. Li, D., Kumaraswamy, E., Harlan-Williams, L. M., & Jensen, R. A. (2013). The role of BRCA1 and BRCA2 in prostate cancer. Frontiers in Bioscience, 18, 1445-1459.
48. Schayek, H., Bentov, I., Jacob-Hirsch, J., Yeung, C., Khanna, C., Helman, L. J., Plymate, S. R., & Werner, H. (2012). Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer. Hormone and Metabolic Research, 44, 511-519.
49. Thomas, R., & Kim, M. H. (2009). A HIF-1alpha-dependent autocrine feedback loop promotes survival of serum-deprived prostate cancer cells. The Prostate, 69, 263-275.
50. Werner, H., Stannard, B., Bach, M. A., LeRoith, D., & Roberts, C. T., Jr. (1990). Cloning and characterization of the proximal promoter region of the rat insulin-like growth factor I (IGF-I) receptor gene. Biochemical and Biophysical Research Communications, 169, 1021-1027. (Pubitemid 20220722)
51. Cooke, D. W., Bankert, L. A., Roberts, C. T., Jr., LeRoith, D., & Casella, S. J. (1991). Analysis of the human type I insulin-like growth factor receptor promoter region. Biochemical and Biophysical Research Communications, 177, 1113-1120.
52. Black, A. R., Black, J. D., & Azizkhan-Clifford, J. (2001). Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. Journal of Cellular Physiology, 188, 143-160. (Pubitemid 32622905)
53. Trybus, T. M., Burgess, A. C., Wojno, K. J., Glover, T. W., & Macoska, J. A. (1996). Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Research, 56, 2263-2267. (Pubitemid 26154070)
54. Narla, G., Heath, K. E., Reeves, H. L., Li, D., Giono, L. E., Kimmelman, A. C., Glucksman, M. J., Narla, J., Eng, F. J., Chan, A. M., Ferrari, A. C., Martignetti, J. A., & Friedman, S. L. (2001). KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science, 294, 2563-2566. (Pubitemid 34027299)
55. Liu, X., Gomez-Pinillos, A., Loder, C., Carrillo-de Santa Pau, E., Qiao, R., Unger, P. D., Kurek, R., Oddoux, C., Melamed, J., Gallagher, R. E., Mandeli, J., & Ferrari, A. C. (2012). KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation. American Journal of Pathology, 181, 1007-1016.
56. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71. (Pubitemid 24345325)
57. Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L. M., Haugen-Strano, A., Swensen, J., Miki, Y., et al. (1994). BRCA1 mutations in primary breast and ovarian carcinomas. Science, 266, 120-122. (Pubitemid 24345332)
58. Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., & Tutt, A. N. (2007). BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, 26, 2126-2132. (Pubitemid 46514749)
59. Chen, Y., Farmer, A. A., Chen, C. F., Jones, D. C., Chen, P. L., & Lee, W. H. (1996). BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Research, 56, 3168-3172. (Pubitemid 26242955)
60. Pandini, G., Mineo, R., Frasca, F., Roberts, C. T., Jr., Marcelli, M., Vigneri, R., & Belfiore, A. (2005). Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Research, 65, 1849-1857. (Pubitemid 40478613)
61. Schayek, H., Seti, H., Greenberg, N. M., Sun, S., Werner, H., & Plymate, S. R. (2010). Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Molecular and Cellular Endocrinology, 323, 239-245.
62. Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013). Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacology & Therapeutics, 140(3), 223-238.
63. Yuan, X., Cai, C., Chen, S., Yu, Z., & Balk, S. P. (2013). Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene, 123(3), 1109-1122.
64. Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005). Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research, 11, 4653-4657. (Pubitemid 41557182)
65. Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research, 68, 4447-4454.
66. Wu, J. D., Haugk, K., Woodke, L., Nelson, P., Coleman, I., & Plymate, S. R. (2006). Interaction of IGF signaling and the androgen receptor in prostate cancer progression. Journal of Cellular Biochemistry, 99, 392-401. (Pubitemid 44435557)
67. Lin, H. K., Yeh, S., Kang, H. Y., & Chang, C. (2001). Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 98, 7200-7205. (Pubitemid 32567926)
68. Wen, Y., Hu, M. C., Makino, K., Spohn, B., Bartholomeusz, G., Yan, D. H., & Hung, M. C. (2000). HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Research, 60, 6841-6845. (Pubitemid 32059149)
69. Manin, M., Baron, S., Goossens, K., Beaudoin, C., Jean, C., Veyssiere, G., Verhoeven, G., & Morel, L. (2002). Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. The Biochemical Journal, 366, 729-736.
70. Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., Vessella, R. L., & Neubauer, B. L. (2000). Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. The Journal of Biological Chemistry, 275, 24500-24505. (Pubitemid 30626543)
71. Murillo, H., Huang, H., Schmidt, L. J., Smith, D. I., & Tindall, D. J. (2001). Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology, 142, 4795-4805. (Pubitemid 33022355)
72. Jiang, Y. G., Luo, Y., He, D. L., Li, X., Zhang, L. L., Peng, T., Li, M. C., & Lin, Y. H. (2007). Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. International Journal of Urology, 14, 1034-1039. (Pubitemid 47621827)
73. Wang, Y., Kreisberg, J. I., & Ghosh, P. M. (2007). Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Current Cancer Drug Targets, 7, 591-604. (Pubitemid 47358145)
74. Li, J., Wang, E., Rinaldo, F., & Datta, K. (2005). Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. Oncogene, 24, 5510-5520. (Pubitemid 43080094)
75. Reiss, K., Wang, J. Y., Romano, G., Furnari, F. B., Cavenee, W. K., Morrione, A., Tu, X., & Baserga, R. (2000). IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene, 19, 2687-2694. (Pubitemid 30326418)
76. Tang, Y., Zhang, D., Fallavollita, L., & Brodt, P. (2003). Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Research, 63, 1166-1171. (Pubitemid 36348689)
77. Tsurusaki, T., Kanda, S., Sakai, H., Kanetake, H., Saito, Y., Alitalo, K., & Koji, T. (1999). Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. British Journal of Cancer, 80, 309-313. (Pubitemid 29210123)
78. Hiraga, T., Myoui, A., Hashimoto, N., Sasaki, A., Hata, K., Morita, Y., Yoshikawa, H., Rosen, C. J., Mundy, G. R., & Yoneda, T. (2012). Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Research, 72, 4238-4249.
79. Li, S., Wang, N., & Brodt, P. (2012). Metastatic cells can escape the proapoptotic effects of TNF-alpha through increased autocrine IL-6/STAT3 signaling. Cancer Research, 72, 865-875.
80. Rojas, A., Liu, G., Coleman, I., Nelson, P. S., Zhang, M., Dash, R., Fisher, P. B., Plymate, S. R., & Wu, J. D. (2011). IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene, 30, 2345-2355.
81. Yap, T. A., Olmos, D., Molife, L. R., & de Bono, J. S. (2011). Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opinion on Investigational Drugs, 20, 1293-1304.
82. Baserga, R. (2013). The decline and fall of the IGF-I receptor. Journal of Cellular Physiology, 228, 675-679.
83. Ozkan, E. E. (2011). Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Molecular and Cellular Endocrinology, 344, 1-24.
84. Rowinsky, E. K., Youssoufian, H., Tonra, J. R., Solomon, P., Burtrum, D., & Ludwig, D. L. (2007). IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clinical Cancer Research, 13, 5549s-5555s. (Pubitemid 47510386)
85. Burtrum, D., Zhu, Z., Lu, D., Anderson, D. M., Prewett, M., Pereira, D. S., Bassi, R., Abdullah, R., Hooper, A. T., Koo, H., Jimenez, X., Johnson, D., Apblett, R., Kussie, P., Bohlen, P., Witte, L., Hicklin, D. J., & Ludwig, D. L. (2003). A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Research, 63, 8912-8921. (Pubitemid 38064071)
86. Plymate, S. R., Haugk, K., Coleman, I., Woodke, L., Vessella, R., Nelson, P., Montgomery, R. B., Ludwig, D. L., & Wu, J. D. (2007). An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clinical Cancer Research, 13, 6429-6439. (Pubitemid 350075033)
87. Wu, J. D., Haugk, K., Coleman, I., Woodke, L., Vessella, R., Nelson, P., Montgomery, R. B., Ludwig, D. L., & Plymate, S. R. (2006). Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clinical Cancer Research, 12, 6153-6160. (Pubitemid 44703781)
88. Wu, J. D., Odman, A., Higgins, L. M., Haugk, K., Vessella, R., Ludwig, D. L., & Plymate, S. R. (2005). In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clinical Cancer Research, 11, 3065-3074. (Pubitemid 40525213)
89. Goel, H. L., Chang, C., Pursell, B., Leav, I., Lyle, S., Xi, H. S., Hsieh, C. C., Adisetiyo, H., Roy-Burman, P., Coleman, I. M., Nelson, P. S., Vessella, R. L., Davis, R. J., Plymate, S. R., & Mercurio, A. M. (2012). VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discovery, 2, 906-921.
90. Beltran, P. J., Mitchell, P., Chung, Y. A., Cajulis, E., Lu, J., Belmontes, B., Ho, J., Tsai, M. M., Zhu, M., Vonderfecht, S., Baserga, R., Kendall, R., Radinsky, R., & Calzone, F. J. (2009). AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular Cancer Therapeutics, 8, 1095-1105.
91. Fahrenholtz, C. D., Beltran, P. J., & Burnstein, K. L. (2013). Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Molecular Cancer Therapeutics, 12, 394-404.
92. Galet, C., Gray, A., Said, J. W., Castor, B., Wan, J., Beltran, P. J., Calzone, F. J., Elashoff, D., Cohen, P., & Aronson, W. J. (2013). Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts. International Journal of Molecular Sciences, 14, 13782-13795.
93. Furukawa, J., Wraight, C. J., Freier, S. M., Peralta, E., Atley, L. M., Monia, B. P., Gleave, M. E., & Cox, M. E. (2010). Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate, 70, 206-218.
94. Smith, M. R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M. C., Bilhartz, D. L., Wynne, C., Murray, R., Zinner, N. R., Schulman, C., Linnartz, R., Zheng, M., Goessl, C., Hei, Y. J., Small, E. J., Cook, R., & Higano, C. S. (2005). Natural history of rising serum prostate-specific antigen inmen with castrate nonmetastatic prostate cancer. Journal of Clinical Oncology, 23, 2918-2925. (Pubitemid 46224110)
95. Nelson, J. B., Love, W., Chin, J. L., Saad, F., Schulman, C. C., Sleep, D. J., Qian, J., Steinberg, J., & Carducci, M. (2008). Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer, 113, 2478-2487.
96. Miller, K., Moul, J. W., Gleave, M., Fizazi, K., Nelson, J. B., Morris, T., Nathan, F. E., McIntosh, S., Pemberton, K., & Higano, C. S. (2013). Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 16, 187-192.
97. Yu, E. Y., Miller, K., Nelson, J., Gleave, M., Fizazi, K., Moul, J. W., Nathan, F. E., & Higano, C. S. (2012). Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. Journal of Urology, 188, 103-109.
98. Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damiao, R., Tammela, T. L., Egerdie, B., Van Poppel, H., Chin, J., Morote, J., Gomez-Veiga, F., Borkowski, T., Ye, Z., Kupic, A., Dansey, R., & Goessl, C. (2012). Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet, 379, 39-46.
99. Higano CS, Alumkal JJ, Ryan CJ, Yu EY, Beer TM, Chandrawansa K, Katz T, Youssoufian H, Schwartz JD. 2009. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody, against the insulin-like growth factor-1 receptor, as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer. J Clin Oncol 27: 15s (suppl; abstr 5142)
100. Higano CS, Alumkal JJ, Ryan CJ, Yu EY, Beer TM, Fox FE, Dontabhaktuni A, Youssoufian H, Schwartz JD. 2010. A phase II study of cixutumumab (IMC-A12), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer: feasibility of every 3-week dosing and updated results. 2010 Genitourinary Cancers Symposium: Abstract 189
101. Rathkopf DE, Danila DC, Chudow JJ, Morris MJ, Slovin SF, Fine S, Fox JJ, Larson SM, Rosen N, Scher HI. 2010. Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer. J Clin Oncol 28:15s (suppl; abstr TPS242)
102. Dean, J. P., Sprenger, C. C., Wan, J., Haugk, K., Ellis, W. J., Lin, D. W., Corman, J. M., Dalkin, B. L., Mostaghel, E., Nelson, P. S., Cohen, P., Montgomery, B., & Plymate, S. R. (2013). Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. Journal of Clinical Endocrinology and Metabolism, 98, E820-E828.
103. Hussain, M., Tangen, C. M., Higano, C., Schelhammer, P. F., Faulkner, J., Crawford, E. D., Wilding, G., Akdas, A., Small, E. J., Donnelly, B., MacVicar, G., Raghavan, D., & Southwest Oncology Group T. (2006). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology, 24, 3984-90. (Pubitemid 46630748)
104. Molife, L. R., Fong, P. C., Paccagnella, L., Reid, A. H., Shaw, H. M., Vidal, L., Arkenau, H. T., Karavasilis, V., Yap, T. A., Olmos, D., Spicer, J., Postel-Vinay, S., Yin, D., Lipton, A., Demers, L., Leitzel, K., Gualberto, A., & de Bono, J. S. (2010). The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. British Journal of Cancer, 103, 332-339.
105. Chi, K. N., Gleave, M. E., Fazli, L., Goldenberg, S. L., So, A., Kollmannsberger, C., Murray, N., Tinker, A., & Pollak, M. (2012). A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clinical Cancer Research, 18, 3407-3413.